Koninklijke Philips NVRYLPF +2.21%72 Debt-to-Equity is 0.71 as of Mar. 2026, which is 37% above its 10-year median of 0.52. GuruFocus rates RYLPF with a GF Score™ of 72/100 and a GF Value™ of $25.50 (Fairly Valued). The stock has 5 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Koninklijke Philips NV ranks worse than 77.87% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Koninklijke Philips NV's Debt-to-Equity or its related term are showing as below:
RYLPF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.52 Max: 0.81
Current: 0.71
During the past 13 years, the highest Debt-to-Equity Ratio of Koninklijke Philips NV was 0.81. The lowest was 0.24. And the median was 0.52.
RYLPF's Debt-to-Equity is ranked worse than 77.87% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs RYLPF: 0.71
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Koninklijke Philips NV Debt-to-Equity Related Terms
Koninklijke Philips NV Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Koninklijke Philips NV's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Koninklijke Philips NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Koninklijke Philips NV Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Koninklijke Philips NV's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Koninklijke Philips NV's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Koninklijke Philips NV (RYLPF) has a Debt-to-Equity of 0.71 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Koninklijke Philips NV and its competitors. This is 37% above median its historical median of 0.52. Over the past decade, Koninklijke Philips NV's Debt-to-Equity has ranged from 0.24 to 0.81. According to the industry distribution chart, Koninklijke Philips NV ranks #549 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 77.9%.
Is Koninklijke Philips NV's Debt-to-Equity too high?
Koninklijke Philips NV's current Debt-to-Equity of 0.71 is 37% above median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 0.81. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Koninklijke Philips NV's value of 0.71 is 208.7% above this industry median. Based on the distribution chart, Koninklijke Philips NV ranks #549 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Koninklijke Philips NV has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Koninklijke Philips NV's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Koninklijke Philips NV ranks #549 out of 705 companies for Debt-to-Equity. This places Koninklijke Philips NV in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Koninklijke Philips NV's value of 0.71 is 208.7% above this benchmark. Historically, Koninklijke Philips NV's own Debt-to-Equity has ranged from 0.24 to 0.81 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 0.23, Koninklijke Philips NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Koninklijke Philips NV's current Debt-to-Equity of 0.71 is 208.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Koninklijke Philips NV and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Koninklijke Philips NV's current Debt-to-Equity is 0.71, which is 37% above median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koninklijke Philips NV stock overvalued right now?
Based on GuruFocus' analysis, Koninklijke Philips NV (RYLPF) is currently considered Fairly Valued. The stock's GF Value™ is $25.50, compared to a current price of $28.01 — trading 9.9% above its estimated fair value. The current Debt-to-Equity is 0.71, which is 37% above median its 10-year median of 0.52 and 208.7% above the Medical Devices & Instruments industry median of 0.23. Koninklijke Philips NV's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Koninklijke Philips NV (RYLPF), the current Debt-to-Equity is 0.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Koninklijke Philips NV (RYLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Koninklijke Philips NV stock appears to be overvalued.
The current stock price of $28.01 is trading 9.9% above its estimated GF Value™ of $25.50.
GuruFocus considers Koninklijke Philips NV to be Fairly Valued.
Key valuation signals for RYLPF:
Debt-to-Equity: 0.71 (37% above median its 10-year median of 0.52)
GF Value™: $25.50 vs. price of $28.01 (9.9% above fair value)
Industry Position: 208.7% above the Medical Devices & Instruments median (#549 of 705)
No single metric tells the full story. See the RYLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
72GF Score
Get the complete analysis for RYLPF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYLPF has been successfully added to your 
